People

Management & Governance

Governance grade: B–. The board is fully refreshed, formally independent on paper, and pay design is conventionally responsive — the 2023–2025 performance share plan vested at zero, and 2025 CEO "Compensation Actually Paid" was only 24% of the headline figure. But Centene is a textbook controlled-by-no-one large-cap: insider ownership is well under 1%, the largest holders are passive index funds, and the company sits inside an active securities class action and a $1B+ multi-state PBM settlement overhang. Skin-in-the-game is policy-driven, not founder-driven.

1. The People Running This Company

The current C-suite is the post-Neidorff team. Sarah London (CEO since March 2022) was promoted from inside after a hand-picked succession; Drew Asher (CFO) is the WellCare CFO who came over with the 2020 deal. The most consequential 2026 move is the addition of two Group Presidents — Dan Finke (ex-Aetna President, ex-CEO Convey Health) and Michael Carson (Wellcare CEO) — sitting between London and the segments. Read this as a defensive layer of operating depth following the 2025 Marketplace morbidity miss.

No Results

London runs Centene at 45 with no prior P&L scale beyond Optum Ventures — she was a technology executive parachuted in 2020 and elevated to CEO 18 months later as Michael Neidorff's health failed. The 2025 Marketplace pricing blowup happened on her watch, and the board's response (two Group Presidents, no CEO change) is a vote of confidence in succession but also an admission that the operating bench needed thickening.

Koster as General Counsel matters more here than at most insurers — Centene is the largest Medicaid contractor in the country and a $1B+ multi-state PBM overcharge settlement was negotiated under his watch.

2. What They Get Paid

CEO total comp was $19.5M for 2025 — flat against 2024's $20.6M despite a $13.53 GAAP loss per share. The pay-for-performance defense is real but selective: the entire 2023–2025 PSU cycle vested at 0% (zero shares delivered) because none of the three metrics — pre-tax earnings CAGR, 2025 net earnings margin, relative TSR — hit threshold. Annual cash bonuses still paid out at 71.6% of target.

No Results

Adjusted diluted EPS fell from $7.17 to $2.08 in 2025 (−71%) and GAAP loss was $(13.53) per share. CEO total compensation dropped only ~5%. The pay design is *technically* working — the 2023–2025 PSUs zeroed out — but headline Summary Compensation Table totals do not reflect the share-price destruction the way "Compensation Actually Paid" eventually does.

CEO-to-median-employee pay ratio is 206× ($19.52M vs $94,800). High, but not outlier for a $20B-cap insurer. Severance arithmetic is the bigger issue: London's involuntary-termination package is $35.7M (cash + accelerated equity), rising to $42.6M on a change of control. Asher: $25.0M / $32.4M. These are large numbers against an entity that just delivered a GAAP loss.

3. Are They Aligned?

This is the weakest section of the file. Centene has no founder, no controlling shareholder, and minuscule officer ownership.

The entire executive-and-director group owns 0.37% of shares — the three index/quant funds together own 73× as much as everyone running the company. This is institutional management, not owner-operator alignment.

Insider buying vs. selling (last 12 months)

No Results

**Positive signal:** CEO Sarah London bought 19,230 shares on the open market at $25.50 on Aug 8, 2025 — directly into the post-blowup capitulation. Director Theodore Samuels added 9,000 shares at $27.62 the prior week. Both sit below today's $40 print. Insider open-market sales (66K shares by departing director Burdick) are explainable; insider open-market buys at the bottom are not — they are conviction.

Capital allocation

Management has been a net buyer of stock: 71.6 million shares repurchased Jan-2023 through Dec-2025, plus $189M of par-value senior notes bought back in 2025. They have also divested 12 non-core businesses (Magellan Rx, Apixio, Circle Health, Operose, etc.) — the empire-building era is being reversed. This is shareholder-friendly behavior.

One small live item: Director Ken Burdick was Executive Chairman of LifeStance Health until March 14, 2026, and Centene continues to pay LifeStance for behavioral-health services under contracts pre-dating his tenure. Disclosed, modest, and arm's-length per the proxy. He is one of the two non-independent directors for this reason.

Skin-in-the-game scorecard

Skin-in-the-Game Score (out of 10)

A middling 5/10. Positives: CEO open-market buy at the bottom; CEO ownership requirement of 6× base salary is met; entire 2023–2025 PSU cycle paid zero shares; share buyback dwarfs dilution. Negatives: total insider stake under 0.4%; severance economics are large in absolute dollars; the "Compensation Actually Paid" framework only flatters the picture because the stock collapsed — pay design did not lead the market down, the market did.

4. Board Quality

Nine nominees. Seven independent under NYSE rules. Median tenure under five years. Mandatory retirement at 75. Audit Chair (Tanji), Comp Chair (Coughlin), Governance Chair (Blume) and Quality Chair (Burdick) — all rotating. Board has been substantially refreshed since the 2021 Politan/Neidorff turbulence.

No Results

**Strength:** Three independent directors (Burdick, Eppinger, Dallas) bring direct healthcare-payer or healthcare-operations experience — Burdick ran WellCare, Dallas ran Medtronic operations, Eppinger ran Hanover/Stewart. Audit Chair Tanji is a former Prudential CFO. **Weakness:** only one director (Burdick) has actual managed-care P&L scars, and zero have direct Medicaid policy / state-contracting backgrounds — the line of business that generated 70% of premium and the largest source of regulatory risk.

There is a live shareholder proposal (John Chevedden) at the May 2026 meeting calling for an Independent Board Chairman. The board recommends AGAINST — but Centene already has a separate Chair (Eppinger) and has had since March 2022, so the proposal is largely cosmetic. It will likely fail.

5. The Verdict

Governance Grade

B–

What is genuinely good. The 2023–2025 PSU cycle paid zero — the formula bites. CEO and a director both bought open-market in the August 2025 panic. Buybacks of 71.6M shares against 491M outstanding (≈14.6% retired in three years) is real capital discipline. Board is properly refreshed, properly independent, and Eppinger as a separate Chair is in place. Audit/Comp/Governance chairs are rotated and credentialled.

What is genuinely concerning. (1) Insider stake is 0.37% — there is no large owner whose net worth pushes back on management on a bad day. (2) The active Hagens Berman class action alleges Centene "inflated enrollment numbers and underestimated patient health risks" between Dec 2024 and Jun 2025 — exactly the period when the Marketplace morbidity miss happened. If discovery turns up internal data showing management knew earlier, this becomes a credibility issue, not just a forecasting one. (3) The legacy Envolve PBM overcharge settlements with 20+ states totaling $1B+ are mostly settled but illustrate the recurring regulatory tax on this business. (4) CEO severance of $35.7M is a lot of money for a CEO who has presided over a GAAP loss and a 50%+ stock drawdown.

What would upgrade this to a B+/A–. Discovery in the securities suit clearing management of pre-disclosure knowledge of the 2025 Marketplace deterioration; meaningful CEO open-market buying (not just the August $490K starter) into a recovery; or a material increase in NEO mandatory ownership multiples.

What would downgrade this to a C. Any indication from class-action discovery that the Marketplace morbidity issue was known internally before public disclosure; a second adverse multi-state settlement; or a Compensation Committee that resets PSU targets downward to "make whole" management for the zero payout.